Gastric Cancer Treatment Market By Treatment Type (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy, Radiation Therapy), By End Use (Hospitals, Clinics, Specialized Cancer Treatment Centers, Ambulatory Surgical Centers) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Gastric Cancer Treatment Market size was valued at USD 9.5 billion in 2022. It is expected to reach USD 25.6 billion by 2028, at a CAGR of 15.3% from 2023 to 2029. Sacral nerve stimulation (SNS) is a therapeutic electrical incitement treatment that is utilized to treat long-haul entrail control and bladder control side effects through the adjustment of nerves controlling the lower urinary tract and pelvic floor. The gastric cancer market is becoming quickly because of expanding occurrence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors over the globe. Significant drivers for the Gastric Cancer Market are treatment progressions, combination therapies, expanding the number of growth treatment focuses, the extensive number of regulatory approvals for metastatic gastric disease and low-measurement radiation innovation-based devices. Moreover, the introduction of novel treatments for metastatic stomach disease is relied upon to drive the development of the Gastric Cancer market soon. However, the absence of sufficient monetary help from medical coverage strategies and stringent regulatory framewok for approving complex nature of radiation devices are the main considerations that can hamper the stomach malignancy advertise development over the figure time frame. Different factors, like, high cost of therapy and monetarily less accessibility of medications for the treatment of Gastric Cancer may hamper the worldwide high cost of therapy.

Gastric Cancer Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

15.3%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
Gastric Cancer Treatment Market Dynamics

Currently, the products available in the market constitutes of a broad assortment of treatment choices, for example, angiogenesis inhibitors, new chemotherapies and HER2-focused on therapy. The worldwide gastric cancer treatment market is becoming quickly attributable to the high extent of people with gastric cancer and the nearness of a solid medication pipeline. To pick up footing in this market, the sellers are assembling and marketing gastric cancer drugs hat display a high wellbeing and adequacy profile, this causes the merchants to pick up a focused edge over their peers. In February 2018, Imugene, an invulnerable oncology organization declared that its malignancy immunization yields promising outcomes in gastric disease clinical preliminary examinations and in September 2017, The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab (Keytruda®) to be utilized on patients with cutting edge gastric cancer growth.

Gastric Cancer Treatment Market Segmentation

By Treatment Type
  • Chemotherapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Surgery
  • Targeted Therapy
By Cancer Type
  • Laryngeal Cancer
  • Lip and Oral Cavity Cancer
  • Nasopharyngeal Cancer
  • Oropharyngeal Cancer
  • Salivary Gland Cancer
  • Others
By End User

Frequently Asked Questions

The gastric cancer treatment market is projected to expand at a CAGR of 15.3% during the forecast period

Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, Pfizer, Inc.

North America is the fastest-growing region for gastric cancer treatment market

Key Features of the Reports

  • The gastric cancer treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Gastric Cancer Treatment Market Introduction 
2.1.Global Gastric Cancer Treatment Market  - Taxonomy
2.2.Global Gastric Cancer Treatment Market  - Definitions
2.2.1. By Treatment Type
2.2.2. By Cancer Type
2.2.3. By End User
2.2.4. By Region
3.Global Gastric Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Gastric Cancer Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Gastric Cancer Treatment Market  By Treatment Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Chemotherapy
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Adjuvant Chemotherapy
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Radiation Therapy
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Surgery
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Targeted Therapy
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Gastric Cancer Treatment Market  By Cancer Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Laryngeal Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Lip and Oral Cavity Cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Nasopharyngeal Cancer
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Oropharyngeal Cancer
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Salivary Gland Cancer
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Gastric Cancer Treatment Market  By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Clinics
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Specialized Cancer Treatment Centers
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Gastric Cancer Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Treatment Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Chemotherapy
9.1.2.Adjuvant Chemotherapy
9.1.3.Radiation Therapy
9.1.4.Surgery
9.1.5.Targeted Therapy
9.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Laryngeal Cancer
9.2.2.Lip and Oral Cavity Cancer
9.2.3.Nasopharyngeal Cancer
9.2.4.Oropharyngeal Cancer
9.2.5.Salivary Gland Cancer
9.2.6.Others
9.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospitals
9.3.2.Clinics
9.3.3.Ambulatory Surgical Centers
9.3.4.Specialized Cancer Treatment Centers
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Chemotherapy
10.1.2.Adjuvant Chemotherapy
10.1.3.Radiation Therapy
10.1.4.Surgery
10.1.5.Targeted Therapy
10.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Laryngeal Cancer
10.2.2.Lip and Oral Cavity Cancer
10.2.3.Nasopharyngeal Cancer
10.2.4.Oropharyngeal Cancer
10.2.5.Salivary Gland Cancer
10.2.6.Others
10.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospitals
10.3.2.Clinics
10.3.3.Ambulatory Surgical Centers
10.3.4.Specialized Cancer Treatment Centers
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Chemotherapy
11.1.2.Adjuvant Chemotherapy
11.1.3.Radiation Therapy
11.1.4.Surgery
11.1.5.Targeted Therapy
11.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Laryngeal Cancer
11.2.2.Lip and Oral Cavity Cancer
11.2.3.Nasopharyngeal Cancer
11.2.4.Oropharyngeal Cancer
11.2.5.Salivary Gland Cancer
11.2.6.Others
11.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospitals
11.3.2.Clinics
11.3.3.Ambulatory Surgical Centers
11.3.4.Specialized Cancer Treatment Centers
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Chemotherapy
12.1.2.Adjuvant Chemotherapy
12.1.3.Radiation Therapy
12.1.4.Surgery
12.1.5.Targeted Therapy
12.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Laryngeal Cancer
12.2.2.Lip and Oral Cavity Cancer
12.2.3.Nasopharyngeal Cancer
12.2.4.Oropharyngeal Cancer
12.2.5.Salivary Gland Cancer
12.2.6.Others
12.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospitals
12.3.2.Clinics
12.3.3.Ambulatory Surgical Centers
12.3.4.Specialized Cancer Treatment Centers
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Chemotherapy
13.1.2.Adjuvant Chemotherapy
13.1.3.Radiation Therapy
13.1.4.Surgery
13.1.5.Targeted Therapy
13.2.  Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Laryngeal Cancer
13.2.2.Lip and Oral Cavity Cancer
13.2.3.Nasopharyngeal Cancer
13.2.4.Oropharyngeal Cancer
13.2.5.Salivary Gland Cancer
13.2.6.Others
13.3.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospitals
13.3.2.Clinics
13.3.3.Ambulatory Surgical Centers
13.3.4.Specialized Cancer Treatment Centers
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Abbott Laboratories, Inc.(U.S)
14.2.2.AstraZeneca plc (U.K)
14.2.3.Eli Lilly and Company(U.S.)
14.2.4.Hoffmann-La Roche Ltd. (Switzerland)
14.2.5.Pfizer, Inc. (U.S.)
14.2.6.GlaxoSmithKline plc (UK)
14.2.7.Amgen, Inc.(U.S)
14.2.8.Celgene corporation (U.S)
14.2.9.Novartis AG (Switzerland)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories, Inc.(U.S)
  • AstraZeneca plc (U.K)
  • Eli Lilly and Company(U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Amgen, Inc.(U.S)
  • Celgene corporation (U.S)
  • Novartis AG (Switzerland)

Adjacent Markets